OncoMatch

OncoMatch/Melanoma/BRAF V600

MelanomaBRAF V600 Clinical Trials

18 recruiting trials·Updated daily from ClinicalTrials.gov

BRAF V600E/K mutations are present in approximately 40–50% of cutaneous melanoma and define the most targetable subgroup. Dabrafenib plus trametinib and encorafenib plus binimetinib are FDA-approved BRAF/MEK inhibitor combinations with high response rates. Trials investigate BRAF/MEK inhibitors combined with PD-1 checkpoint therapy for durable benefit, triple combinations targeting ERK/PI3K co-escape pathways, and adjuvant targeted therapy strategies.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting BRAF V600 Melanoma trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

ETOP IBCSG Partners Foundation

Phase 2/Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Cancer Research UK

Phase 2331 US sites

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 1/Phase 211 US sites

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Georgiamune Inc

Phase 21 US site

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

M.D. Anderson Cancer Center

Phase 1/Phase 21 US site

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

University of Louisville

Additional trials

More BRAF V600 Melanoma trials

Phase 1
NCT05538130A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsPhase 157 US sitesNCT05355701A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Phase 131 US sitesNCT06326411A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsPhase 117 US sitesNCT04903119Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaPhase 14 US sitesNCT07224425A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it HelpsPhase 12 US sitesNCT05098210Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerPhase 11 US siteNCT04741997Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaEarly Phase 11 US site
5 international trials (no US sites)
Other Melanoma biomarkers

Browse other molecular targets with active Melanoma trials.

NRASKITPD-L1 (CD274)
← All Melanoma clinical trials